Tevogen

TVGNW · NASDAQ

$0.0672+$0.0022 (+3.38%)TodayMarket closed · Oct 23, 4:00 PM ET

Prev close $0.065

Latest news

Press releaseOct 8, 3:50 PM ETGlobe Newswire
UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
Press releaseOct 8, 2:10 PM ETGlobe Newswire
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
Press releaseJul 29, 8:00 AM ETGlobe Newswire
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
Press releaseJul 13, 10:15 PM ETGlobe Newswire
Tevogen Bio Announces 2026 Annual Meeting of Stockholders
Press releaseJun 9, 3:30 PM ETGlobe Newswire
Tevogen Announces Formation of a Healthcare Services Initiative
Press releaseMay 28, 12:30 PM ETGlobe Newswire
Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue
Press releaseMay 21, 12:15 PM ETGlobe Newswire
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization
Press releaseMay 18, 12:15 PM ETGlobe Newswire
Letter to Shareholders from CEO Dr. Ryan Saadi
Press releaseMay 12, 11:45 AM ETGlobe Newswire
Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close
Press releaseApr 27, 11:49 AM ETGlobe Newswire
Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal
Press releaseMar 13, 2:45 PM ETGlobe Newswire
Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization
Press releaseFeb 27, 2:20 PM ETGlobe Newswire
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization
Press releaseFeb 26, 4:22 PM ETGlobe Newswire
UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus
Press releaseJan 30, 3:00 PM ETGlobe Newswire
Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders
Press releaseNov 5, 3:20 PM ETGlobe Newswire
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
Press releaseNov 26, 8:05 AM ETGlobe Newswire
Tevogen Bio Prepares Organizational Readiness to Support Company's Growth Strategy
Press releaseAug 22, 9:00 AM ETGlobe Newswire
Tevogen Bio Secures $6 Million Series C Preferred Stock Investment
Press releaseAug 15, 9:00 AM ETGlobe Newswire
Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC

Tevogen Bio Holdings Inc. Becomes Tevogen Inc.

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

Tevogen Announces Formation of a Healthcare Services Initiative

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

Letter to Shareholders from CEO Dr. Ryan Saadi

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

Tevogen Bio Prepares Organizational Readiness to Support Company's Growth Strategy

Tevogen Bio Secures $6 Million Series C Preferred Stock Investment

Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares